Terms: = Ovarian cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Treatment
22 results:
1. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of apatinib combined with liposomal doxorubicin or paclitaxel versus liposomal doxorubicin or paclitaxel monotherapy in patients with recurrent platinum-resistant ovarian cancer.
Yang H; Geng A; Wang Z; Wu C
J Obstet Gynaecol Res; 2023 Jun; 49(6):1611-1619. PubMed ID: 36988159
[TBL] [Abstract] [Full Text] [Related]
3. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
[TBL] [Abstract] [Full Text] [Related]
4. Translation and validation of the Chinese version of the MD Anderson symptom inventory for measuring perioperative symptom burden in patients with gynecologic cancer.
Zhang T; Zheng YY; Yang ZR; Shi Q; Wang XS; Zhao J; Yang M; Wu CL; Wang GR
BMC Womens Health; 2021 Jul; 21(1):276. PubMed ID: 34325677
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
Yan S; Fang J; Chen Y; Xie Y; Zhang S; Zhu X; Fang F
BMC Cancer; 2020 Dec; 20(1):1205. PubMed ID: 33287740
[TBL] [Abstract] [Full Text] [Related]
6. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer.
Dackus GMHE; Jóźwiak K; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Sonke GS; Linn SC
Breast Cancer Res Treat; 2021 Feb; 185(3):817-830. PubMed ID: 33113088
[TBL] [Abstract] [Full Text] [Related]
7. Patients triaged to neoadjuvant chemotherapy have higher rates of sarcopenia: An opportunity for prehabilitation.
Fadadu PP; Polen-De CL; McGree ME; Weaver AL; Moynagh MR; Takahashi N; Langstraat CL; Cliby WA; Kumar A
Gynecol Oncol; 2021 Jan; 160(1):40-44. PubMed ID: 33109391
[TBL] [Abstract] [Full Text] [Related]
8. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
Olafsdottir EJ; Borg A; Jensen MB; Gerdes AM; Johansson ALV; Barkardottir RB; Johannsson OT; Ejlertsen B; Sønderstrup IMH; Hovig E; Lænkholm AV; Hansen TVO; Olafsdottir GH; Rossing M; Jonasson JG; Sigurdsson S; Loman N; Nilsson MP; Narod SA; Tryggvadottir L
Br J Cancer; 2020 Nov; 123(11):1608-1615. PubMed ID: 32939053
[TBL] [Abstract] [Full Text] [Related]
9. Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.
Breen AF; Scurr D; Cassioli ML; Wells G; Thomas NR; Zhang J; Turyanska L; Bradshaw TD
Int J Nanomedicine; 2019; 14():9525-9534. PubMed ID: 31824148
[TBL] [Abstract] [Full Text] [Related]
10. Involvement of NORAD/miR-608/STAT3 axis in carcinostasis effects of physcion 8-O-β-glucopyranoside on ovarian cancer cells.
Yang X; Yan Y; Chen Y; Li J; Yang J
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2855-2865. PubMed ID: 31299866
[TBL] [Abstract] [Full Text] [Related]
11. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Vergote I; Coens C; Nankivell M; Kristensen GB; Parmar MKB; Ehlen T; Jayson GC; Johnson N; Swart AM; Verheijen R; McCluggage WG; Perren T; Panici PB; Kenter G; Casado A; Mendiola C; Stuart G; Reed NS; Kehoe S; ;
Lancet Oncol; 2018 Dec; 19(12):1680-1687. PubMed ID: 30413383
[TBL] [Abstract] [Full Text] [Related]
12. A Comparative Analysis of Survival and Funding Discrepancies in cancers With High Mortality.
Hall BR; Cannon A; Atri P; Wichman CS; Smith LM; Kumar S; Batra SK; Wang H; Ganti AK; Sasson AR; Are C
Ann Surg; 2020 Feb; 271(2):296-302. PubMed ID: 30188400
[TBL] [Abstract] [Full Text] [Related]
13. Current detection rates and time-to-detection of all identifiable
Manchanda R; Blyuss O; Gaba F; Gordeev VS; Jacobs C; Burnell M; Gan C; Taylor R; Turnbull C; Legood R; Zaikin A; Antoniou AC; Menon U; Jacobs I
J Med Genet; 2018 Aug; 55(8):538-545. PubMed ID: 29622727
[TBL] [Abstract] [Full Text] [Related]
14. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract] [Full Text] [Related]
15. Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of ovarian cancer Residual Disease.
Eetezadi S; De Souza R; Vythilingam M; Lessa Cataldi R; Allen C
Mol Pharm; 2015 Nov; 12(11):3973-85. PubMed ID: 26394060
[TBL] [Abstract] [Full Text] [Related]
16. [Bilateral metastases of renal cell carcinoma to the ovaries--a case report].
Hołody-Zareba J; Kinalski P; Sulkowski S; Kozłowski R; Kinalski M
Ginekol Pol; 2013 Jul; 84(7):650-3. PubMed ID: 24032280
[TBL] [Abstract] [Full Text] [Related]
17. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Lee CK; Gurney H; Brown C; Sorio R; Donadello N; Tulunay G; Meier W; Bacon M; Maenpaa J; Petru E; Reed N; Gebski V; Pujade-Lauraine E; Lord S; Simes RJ; Friedlander M
Br J Cancer; 2011 Jul; 105(3):360-5. PubMed ID: 21750553
[TBL] [Abstract] [Full Text] [Related]
18. Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Holloway RW; Grendys EC; Lefebvre P; Vekeman F; McMeekin S
Oncologist; 2010; 15(10):1073-82. PubMed ID: 20930103
[TBL] [Abstract] [Full Text] [Related]
19. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract] [Full Text] [Related]
20. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract] [Full Text] [Related]
[Next]
